You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聖諾醫藥-B(02257.HK)將於美國披露肝臟靶向技術平台進展
阿思達克 03-15 09:19
聖諾醫藥-B(02257.HK)公布,將於美國東部時間今日(15日)在美國波士頓OPT會議上公布其GalNAc-肝臟靶向技術平台的最新進展和相關產品管線拓展。 公司的GalAhead遞送平台將GalNAc靶向分子與獨特的RNAi觸發器結構結合,可以同時靶向一個(mxRNA)或多個(muRNA)基因的mRNA分子。 公司首席技術官Dmitry Samarsky將通過演講,提供數據證明mxRNA在原代肝細胞(體外)和小鼠(體內)中的功效;介紹一項為期33周的非人類靈長類動物研究結果,該研究使用GalAhead治療項目STP122G的候選藥物分子,靶向凝血因子XI,並報告基於GalAhead的其他治療項目取得的進展。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account